Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61st American Society of Hematology (ASH)  Annual Meeting &…
Browsing: Immunotherapy
Loui Madakamutil, PhD of Nektar Therapeutics discusses new preclinical Ddta for its IL-15 agonist, NKTR-255 at ASH 2019. ___________ Read…
Mark Sellmyer, MD, PhD @sellmyerlab of @PennMedicine explains how CAR-T cell imaging markers will affect treatment and clinicians. ___________ Read…
Mark Sellmyer, Md, PhD @sellmyerlab of @PennMedicine answers how sensitive is this technology? ___________ Read here: https://www.eurekalert.org/pub_releases/2019-11/uops-tmc110519.php
Mark Sellmyer, MD, PhD sellmyerlab of @PennMedicine discusses to monitor cancer therapy, researchers tag CAR-T cells with imaging markers. ___________…
Daniel M. Rotroff, PhD of @CleClinicMD answers will this affect clinicians and treatment today on anti-PD-1/PD-L1 antibody immunotherapy. _________ Read…
Daniel M. Rotroff, PhD of @CleClinicMD answers commonly asked questions to anti-PD-1/PD-L1 antibody immunotherapy. _________ Read here: https://ascopubs.org/doi/full/10.1200/JCO.19.01712
Daniel M. Rotroff, PhD of @CleClinicMD discusses the response to anti-PD-1/PD-L1 antibody immunotherapy. __________ Read here: https://ascopubs.org/doi/full/10.1200/JCO.19.01712
-Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study–Expansion cohort in head and neck squamous cell carcinoma…
Alena Gros of @VHIO answers commonly asked questions regarding the development of cell therapies for non-responders to current immunotherapies: can…
Alena Gros of @VHIO explains driving the development of cell therapies for non-responders to current immunotherapies. __________ Research conducted by…
Research conducted by VHIO’s Alena Gros suggests a modern, less intrusive approach to detecting killer T lymphocytes in patients with…
Lee P. Richman, MD, Andrew J. Rech, MD and Robert H. Vonderheide, MD of @PennMedicine answer how it is different…
Lee P. Richman, MD, Andrew J. Rech, MD and Robert H. Vonderheide, MD of @PennMedicine discuss an algorithm personalizes which…
When tumor cells expand, tens of thousands of genetic mutations are often spawned. It’s like finding a few needles in…
New multi-pronged strategy for treating advanced breast cancer earns Breakthrough Award Multifaceted approach combines 3 complementary immunotherapy strategies Two clinical…
Immunotherapies are amazing drugs against cancer. However, they still fail for too many patients. This video series presents IMPRES and…
Michael B. Atkins at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology elaborates on the…
Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology provides some…
Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses the…
Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses how…
Elad Sharon MD @EladSharonMD Of The National Cancer Institute Discusses Pembrolizumab Trial & Broadening Eligibility For HIV Patients: Patients With…
Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses TEDOPI: A Patented Combination Of 10 Neo-Epitopes. TEDOPI Is Being Evaluated In…
Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses TEDOPI Trials: NSCLC Trial Results In 2020, Primary Endpoint Is Overall Survival,…
Alexis Peyroles MBA CEO Of OSE Immunotherapeutics Discusses OSE Immunotherapeutics: French Company Based In Paris Focusing On How To Prolong…
Frederic Ors BS Of IMV, Inc. Discusses DeCidE1 study: Looking At Tumor Aggression After Treatment, Up To 30 Month Clinical…
Frederic Ors BS Of IMV, Inc. Discusses DeCidE1 study Questions: Why Not Use This Treatment In Earlier Stage Or Even…
Elizabeth Buchbinder MD Of DFCI Discusses SITC Advances In Cancer Immunotherapy: Great Opportunity For Clinicians To Learn About All The…
GRACE – Global Resource for Advancing Cancer Education Published on Jan 15, 2016 Terrie Schmith, a stage IV melanoma survivor,…
GRACE – Global Resource for Advancing Cancer Education Published on Jan 18, 2016 Dr. James Gulley, National Cancer Institute, discusses…
Dr. Ben Levy discusses two trials that are trying to determine if Immunotherapy can help lung cancer patients with earlier…
Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and…
Immune checkpoint inhibitors are now becoming approved and commercially available for patients with previously treated advanced NSCLC. Dr. Eddie Garon,…
Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used…
Drs. Leora Horn, Ben Solomon, & Jack West assess whether clinical factors such as being a never-smoker or having a…
Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies…
Dr. Jack West reviews the concept of epigenetics, epigenetic priming, and whether oral azacytidine can improve outcomes in patients who…
As we learn more about immunotherapy for lung cancer, combinations with multiple immunotherapy agents are being explored. Medical oncologist Dr.…
Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of “pseudoprogression”.
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Should Patients In The 1st Line Setting Should Receive…
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Aimwithimmunotherapy.org And The Various Resources The Site Provides For Patients And…
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Whats Next With Aimwithimmunotherapy.org. For More Info Visit: Aimwithimmunotherapy.org
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Benefits Of Aimwithimmunotherapy.org And The Various Resources It Provides For Patients…
Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Assessment & Education Regarding (irAEs). For More Info Visit: Aimwithimmunotherapy.org
Dr. Julie Brahmer, Johns Hopkins University, discusses immunotherapies for NSCLC and SCLC, analyzes the relevant trial data and addresses the…
Dr. Julie Brahmer, Johns Hopkins University, discusses the use of biomarker testing and mutational burden to select patients for specific…
Kathleen Mahoney, M.D. Instructor, Medicine, Harvard Medical School Discusses Protein Biomarkers, PD-L1, & Multifactorial. At the Seventeenth International Kidney Cancer…
Kathleen Mahoney, M.D. Instructor, Medicine, Harvard Medical School Discusses Is The Secreted Variant Of PD-L1 A Systemic Immunosuppressant. At the…
Kathleen Mahoney, M.D. Instructor, Medicine, Harvard Medical School Discusses Data Regarding A Splice Variant Of PD-L1. At the Seventeenth International…
Rana Mckay, M.D. Medical Oncologist, Assistant Professor of Medicine at The University Of California San Diego, discusses VEGF Plus Radium…